## **Healthy Control Inclusion/Exclusion Criteria**

O of 12 completed **Assessment Date** 09/22/2020 **Inclusion Criteria** 1. Male or female age 30 years or older at Screening visit. No Yes 2. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 halflives before DaTscan imaging. No Yes 3. Confirmation that participant is eligible based on Screening DaTscan imaging. No Yes 4. Able to provide informed consent. No Yes 5. Women may not be pregnant, lactating or planning pregnancy during the study. Yes No Includes a negative pregnancy test on day of Screening DaTscan imaging test prior to injection of DaTscan.

Exclusion Criteria		
1. First degree relative with PD (parent, sibli	ng, child).	
○ No	Yes	
2. Current or active clinically significant neurological disorder (in the opinion of the Investigator).		
○ No	Yes	
3. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).		
○ No	Yes	
4. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.		
○ No	Yes	
5. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture.		
○ No	Yes	
6. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.		
○ No	Yes	
7. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.		
○ No	Yes	